CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Eltrombopagdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03243656
NCT03243656Phase 4Completed

Randomized Clinical Trial of the Use of & Cyclosporine in Children With Sever Idiopathic Aplastic Anemia

Assiut University·interventional·Posted Aug 9, 2017·Updated Jan 18, 2022

In Brief

A Phase 4 clinical trial evaluating Eltrombopag for Eltrombopag. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Aplastic anemia is a rare disorder characterized by pancytopenia and a hypo cellular bone marrow.but,It is very serious disease causing morbidity and mortality. Aplastic anemia can be treated effectively with haematopoietic stem cell transplantation and immunosuppressive drug regimens but haematopoietic stem cell transplantation has limitations due to its cost and many patient are unsuitable. Immunosuppressive drug has a significant number of patients have persistent cytopenias. Currently, the treatment of these patients is regular transfusion, which are expensive, inconvenient, and associated with serious side effects related to iron overload and transfusion. Eltrombopag is an oral thrombopoietin mimetic that selectively binds at the transmembrane and juxtamembrane domains of the thrombopoietin receptor, at sites distinct from the binding site of thrombopoietin therefore it does not compete for binding with the native molecule. It promoting thrombopoiesis and release of platelets from mature megakaryocytes. Also, promote other hematopoietic stem cell as well as in thrombopoiesis .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEltrombopag
CountriesEgypt
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 9, 2017
Enrollment StartDec 20, 2017
Primary CompletionDec 29, 2019
Study CompletionJan 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.9 years ago

Interventions

Eltrombopagdrug

An oral thrombopoietin receptor agonist